PDF herunterladen
Semin Neurol 2010; 30(2): 201-211
DOI: 10.1055/s-0030-1249228
© Thieme Medical Publishers

Management of Migraine Headache in the Emergency Department

Carrie E. Robertson1 , David F. Black2 , Jerry W. Swanson1
  • 1Department of Neurology, Mayo Clinic, Rochester, Minnesota
  • 2Department of Radiology, Mayo Clinic, Rochester, Minnesota
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
29. März 2010 (online)

    Lizenzen und Reprints

ABSTRACT

Headache is one of the more common reasons for adults to visit an emergency department. Most of these visits are for primary headache disorders, most commonly migraine headache. The authors discuss management options for patients presenting to the emergency department with prolonged, severe, or refractory migraine headaches. Particular attention is given to parenteral treatments and protocols that would not be options as an outpatient. The epidemiology, investigation, and outpatient management of migraine headache are discussed in other articles in this issue.

KEYWORDS

Headache - migraine - status migrainosus - triptan - dihydroergotamine

REFERENCES

  • 1 Pitts S R, Niska R W, Xu J, Burt C W. National Hospital Ambulatory Medical Care Survey: 2006 emergency department summary.  Natl Health Stat Report. 2008;  (7) 1-38
    PubMedGoogle Scholar
  • 2 Goldstein J N, Camargo Jr C A, Pelletier A J, Edlow J A. Headache in United States emergency departments: demographics, work-up and frequency of pathological diagnoses.  Cephalalgia. 2006;  26(6) 684-690
    CrossrefPubMedGoogle Scholar
  • 3 Friedman B W, Hochberg M L, Esses D et al.. Applying the International Classification of Headache Disorders to the emergency department: an assessment of reproducibility and the frequency with which a unique diagnosis can be assigned to every acute headache presentation.  Ann Emerg Med. 2007;  49(4) 409-419 e1-e9
    CrossrefPubMedGoogle Scholar
  • 4 Silberstein S D, Freitag F G, Bigal M E. Migraine treatment. In: Silberstein SD, Lipton RB, Dodick DW Wolff's Headache. 8th ed. Oxford; Oxford University Press 2008
    Google Scholar
  • 5 Vinson D R, Drotts D L. Diphenhydramine for the prevention of akathisia induced by prochlorperazine: a randomized, controlled trial.  Ann Emerg Med. 2001;  37(2) 125-131
    CrossrefPubMedGoogle Scholar
  • 6 Lake C R, Casey D E, McEvoy J P, Siris S G, Boyer W F, Simpson G. Anticholinergic prophylaxis in young adults treated with neuroleptic drugs.  Psychopharmacol Bull. 1986;  22(3) 981-984
    PubMedGoogle Scholar
  • 7 Silberstein S D, Young W B, Mendizabal J E, Rothrock J F, Alam A S. Acute migraine treatment with droperidol: A randomized, double-blind, placebo-controlled trial.  Neurology. 2003;  60(2) 315-321
    PubMedGoogle Scholar
  • 8 Wang S J, Silberstein S D, Young W B. Droperidol treatment of status migrainosus and refractory migraine.  Headache. 1997;  37(6) 377-382
    CrossrefPubMedGoogle Scholar
  • 9 Weaver C S, Jones J B, Chisholm C D et al.. Droperidol vs prochlorperazine for the treatment of acute headache.  J Emerg Med. 2004;  26(2) 145-150
    CrossrefPubMedGoogle Scholar
  • 10 Miner J R, Fish S J, Smith S W, Biros M H. Droperidol vs. prochlorperazine for benign headaches in the emergency department.  Acad Emerg Med. 2001;  8(9) 873-879
    CrossrefPubMedGoogle Scholar
  • 11 Jones J, Sklar D, Dougherty J, White W. Randomized double-blind trial of intravenous prochlorperazine for the treatment of acute headache.  JAMA. 1989;  261(8) 1174-1176
    CrossrefPubMedGoogle Scholar
  • 12 Coppola M, Yealy D M, Leibold R A. Randomized, placebo-controlled evaluation of prochlorperazine versus metoclopramide for emergency department treatment of migraine headache.  Ann Emerg Med. 1995;  26(5) 541-546
    CrossrefPubMedGoogle Scholar
  • 13 Jones J, Pack S, Chun E. Intramuscular prochlorperazine versus metoclopramide as single-agent therapy for the treatment of acute migraine headache.  Am J Emerg Med. 1996;  14(3) 262-264
    CrossrefPubMedGoogle Scholar
  • 14 Tanen D A, Miller S, French T, Riffenburgh R H. Intravenous sodium valproate versus prochlorperazine for the emergency department treatment of acute migraine headaches: a prospective, randomized, double-blind trial.  Ann Emerg Med. 2003;  41(6) 847-853
    CrossrefPubMedGoogle Scholar
  • 15 Seim M B, March J A, Dunn K A. Intravenous ketorolac vs intravenous prochlorperazine for the treatment of migraine headaches.  Acad Emerg Med. 1998;  5(6) 573-576
    CrossrefPubMedGoogle Scholar
  • 16 Sun-Edelstein C, Mauskop A. Role of magnesium in the pathogenesis and treatment of migraine.  Expert Rev Neurother. 2009;  9(3) 369-379
    CrossrefPubMedGoogle Scholar
  • 17 Bigal M E, Bordini C A, Speciali J G. Intravenous chlorpromazine in the acute treatment of episodic tension-type headache: a randomized, placebo controlled, double-blind study.  Arq Neuropsiquiatr. 2002;  60(3-A, 3-A) 537-541
    PubMedGoogle Scholar
  • 18 Bell R, Montoya D, Shuaib A, Lee M A. A comparative trial of three agents in the treatment of acute migraine headache.  Ann Emerg Med. 1990;  19(10) 1079-1082
    CrossrefPubMedGoogle Scholar
  • 19 Kelly A M, Walcynski T, Gunn B. The relative efficacy of phenothiazines for the treatment of acute migraine: a meta-analysis.  Headache. 2009;  49(9) 1324-1332
    CrossrefPubMedGoogle Scholar
  • 20 Colman I, Brown M D, Innes G D, Grafstein E, Roberts T E, Rowe B H. Parenteral metoclopramide for acute migraine: meta-analysis of randomised controlled trials.  BMJ. 2004;  329(7479) 1369-1373
    CrossrefPubMedGoogle Scholar
  • 21 Ellis G L, Delaney J, DeHart D A, Owens A. The efficacy of metoclopramide in the treatment of migraine headache.  Ann Emerg Med. 1993;  22(2) 191-195
    PubMedGoogle Scholar
  • 22 Tek D S, McClellan D S, Olshaker J S, Allen C L, Arthur D C. A prospective, double-blind study of metoclopramide hydrochloride for the control of migraine in the emergency department.  Ann Emerg Med. 1990;  19(10) 1083-1087
    CrossrefPubMedGoogle Scholar
  • 23 Rapoport A M, Silberstein S D. Emergency treatment of headache.  Neurology. 1992;  42(3, Suppl 2) 43-44
    PubMedGoogle Scholar
  • 24 Perry C M, Markham A. Sumatriptan. An updated review of its use in migraine.  Drugs. 1998;  55(6) 889-922
    CrossrefPubMedGoogle Scholar
  • 25 Lobo B L, Cooke S C, Landy S H. Symptomatic pharmacotherapy of migraine.  Clin Ther. 1999;  21(7) 1118-1130
    CrossrefPubMedGoogle Scholar
  • 26 Salonen R, Scott A. Triptans: do they differ?.  Curr Pain Headache Rep. 2002;  6(2) 133-139
    CrossrefPubMedGoogle Scholar
  • 27 Mett A, Tfelt-Hansen P. Acute migraine therapy: recent evidence from randomized comparative trials.  Curr Opin Neurol. 2008;  21(3) 331-337
    CrossrefPubMedGoogle Scholar
  • 28 Tfelt-Hansen P, De Vries P, Saxena P R. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy.  Drugs. 2000;  60(6) 1259-1287
    CrossrefPubMedGoogle Scholar
  • 29 Rapoport A M, Tepper S J, Bigal M E, Sheftell F D. The triptan formulations: how to match patients and products.  CNS Drugs. 2003;  17(6) 431-447
    CrossrefPubMedGoogle Scholar
  • 30 Silberstein S D, McCrory D C. Ergotamine and dihydroergotamine: history, pharmacology, and efficacy.  Headache. 2003;  43(2) 144-166
    CrossrefPubMedGoogle Scholar
  • 31 Raskin N H. Treatment of status migrainosus: the American experience.  Headache. 1990;  30(Suppl 2) 550-553
    CrossrefPubMedGoogle Scholar
  • 32 Ford R G, Ford K T. Continuous intravenous dihydroergotamine in the treatment of intractable headache.  Headache. 1997;  37(3) 129-136
    CrossrefPubMedGoogle Scholar
  • 33 Swidan S Z, Lake III A E, Saper J R. Efficacy of intravenous diphenhydramine versus intravenous DHE-45 in the treatment of severe migraine headache.  Curr Pain Headache Rep. 2005;  9(1) 65-70
    CrossrefPubMedGoogle Scholar
  • 34 Saadah H A. Abortive migraine therapy in the office with dexamethasone and prochlorperazine.  Headache. 1994;  34(6) 366-370
    CrossrefPubMedGoogle Scholar
  • 35 Jakubowski M, Levy D, Goor-Aryeh I, Collins B, Bajwa Z, Burstein R. Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors.  Headache. 2005;  45(7) 850-861
    CrossrefPubMedGoogle Scholar
  • 36 Krymchantowski A V. The use of combination therapies in the acute management of migraine.  Neuropsychiatr Dis Treat. 2006;  2(3) 293-297
    CrossrefPubMedGoogle Scholar
  • 37 Brandes J L, Kudrow D, Stark S R et al.. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial.  JAMA. 2007;  297(13) 1443-1454
    CrossrefPubMedGoogle Scholar
  • 38 Baden E Y, Hunter C J. Intravenous dexamethasone to prevent the recurrence of benign headache after discharge from the emergency department: a randomized, double-blind, placebo-controlled clinical trial.  CJEM. 2006;  8(6) 393-400
    PubMedGoogle Scholar
  • 39 Rowe B H, Colman I, Edmonds M L, Blitz S, Walker A, Wiens S. Randomized controlled trial of intravenous dexamethasone to prevent relapse in acute migraine headache.  Headache. 2008;  48(3) 333-340
    CrossrefPubMedGoogle Scholar
  • 40 Fiesseler F W, Shih R, Szucs P et al.. Steroids for migraine headaches: a randomized double-blind, two-armed, placebo-controlled trial.  J Emerg Med. 2009;  , October 19 (Epub ahead of print)
    PubMedGoogle Scholar
  • 41 Singh A, Alter H J, Zaia B. Does the addition of dexamethasone to standard therapy for acute migraine headache decrease the incidence of recurrent headache for patients treated in the emergency department? A meta-analysis and systematic review of the literature.  Acad Emerg Med. 2008;  15(12) 1223-1233
    CrossrefPubMedGoogle Scholar
  • 42 Colman I, Friedman B W, Brown M D et al.. Parenteral dexamethasone for acute severe migraine headache: meta-analysis of randomised controlled trials for preventing recurrence.  BMJ. 2008;  336(7657) 1359-1361
    CrossrefPubMedGoogle Scholar
  • 43 Gallagher R M. Emergency treatment of intractable migraine.  Headache. 1986;  26(2) 74-75
    CrossrefPubMedGoogle Scholar
  • 44 Rozen T D. Acute therapy for migraine headaches.  Semin Neurol. 2006;  26(2) 181-187
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 45 Edwards K R, Norton J, Behnke M. Comparison of intravenous valproate versus intramuscular dihydroergotamine and metoclopramide for acute treatment of migraine headache.  Headache. 2001;  41(10) 976-980
    CrossrefPubMedGoogle Scholar
  • 46 Mathew N T, Kailasam J, Meadors L, Chernyschev O, Gentry P. Intravenous valproate sodium (depacon) aborts migraine rapidly: a preliminary report.  Headache. 2000;  40(9) 720-723
    CrossrefPubMedGoogle Scholar
  • 47 Cete Y, Dora B, Ertan C, Ozdemir C, Oktay C. A randomized prospective placebo-controlled study of intravenous magnesium sulphate vs. metoclopramide in the management of acute migraine attacks in the emergency department.  Cephalalgia. 2005;  25(3) 199-204
    CrossrefPubMedGoogle Scholar
  • 48 Corbo J, Esses D, Bijur P E, Iannaccone R, Gallagher E J. Randomized clinical trial of intravenous magnesium sulfate as an adjunctive medication for emergency department treatment of migraine headache.  Ann Emerg Med. 2001;  38(6) 621-627
    CrossrefPubMedGoogle Scholar
  • 49 Bigal M E, Bordini C A, Tepper S J, Speciali J G. Intravenous magnesium sulphate in the acute treatment of migraine without aura and migraine with aura. A randomized, double-blind, placebo-controlled study.  Cephalalgia. 2002;  22(5) 345-353
    CrossrefPubMedGoogle Scholar
  • 50 Mauskop A, Altura B T, Cracco R Q, Altura B M. Intravenous magnesium sulfate rapidly alleviates headaches of various types.  Headache. 1996;  36(3) 154-160
    CrossrefPubMedGoogle Scholar
  • 51 Friedman B W, Kapoor A, Friedman M S, Hochberg M L, Rowe B H. The relative efficacy of meperidine for the treatment of acute migraine: a meta-analysis of randomized controlled trials.  Ann Emerg Med. 2008;  52(6) 705-713
    CrossrefPubMedGoogle Scholar
  • 52 Ho T W, Mannix L K, Fan X MK-0974 Protocol 004 study group et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine.  Neurology. 2008;  70(16) 1304-1312
    CrossrefPubMedGoogle Scholar
  • 53 Ho T W, Ferrari M D, Dodick D W et al.. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial.  Lancet. 2008;  372(9656) 2115-2123
    CrossrefPubMedGoogle Scholar
  • 54 Connor K M, Shapiro R E, Diener H C et al.. Randomized, controlled trial of telcagepant for the acute treatment of migraine.  Neurology. 2009;  73(12) 970-977
    CrossrefPubMedGoogle Scholar
  • 55 Petersen K A, Birk S, Lassen L H et al.. The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers.  Cephalalgia. 2005;  25(2) 139-147
    CrossrefPubMedGoogle Scholar
  • 56 Olesen J, Diener H C, Husstedt I W BIBN 4096 BS Clinical Proof of Concept Study Group et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine.  N Engl J Med. 2004;  350(11) 1104-1110
    CrossrefPubMedGoogle Scholar
  • 57 Villalon C M, Olesen J. The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs.  Pharmacol Ther. 2009;  124(3) 309-323
    CrossrefPubMedGoogle Scholar
  • 58 Headache Classification Subcommittee of the International Headache Society . The international classification of headache disorders, 2nd edition.  Cephalalgia. 2004;  24(Suppl 1) 1-160
    PubMedGoogle Scholar
  • 59 Capobianco D J, Dodick D W. Diagnosis and treatment of cluster headache.  Semin Neurol. 2006;  26(2) 242-259
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 60 The Sumatriptan Cluster Headache Study Group . Treatment of acute cluster headache with sumatriptan.  N Engl J Med. 1991;  325(5) 322-326
    CrossrefPubMedGoogle Scholar
  • 61 Dodick D W, Capobianco D J. Treatment and management of cluster headache.  Curr Pain Headache Rep. 2001;  5(1) 83-91
    CrossrefPubMedGoogle Scholar
  • 62 Kudrow L. Cluster Headache. Mechanisms and Management. Oxford; Oxford University Press 1980
    Google Scholar
  • 63 Mathew N T. Cluster headache.  Semin Neurol. 1997;  17(4) 313-323
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 64 Loder E. Migraine in pregnancy.  Semin Neurol. 2007;  27(5) 425-433
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 65 Menon R, Bushnell C D. Headache and pregnancy.  Neurologist. 2008;  14(2) 108-119
    CrossrefPubMedGoogle Scholar
  • 66 Briggs G G, Freeman R K, Yaffe S J. Drugs in Pregnancy and Lactation. 8th ed. Philadelphia; Lippincott Williams & Wilkins 2008
    Google Scholar
  • 67 Marcus D A. Managing headache during pregnancy and lactation.  Expert Rev Neurother. 2008;  8(3) 385-395
    CrossrefPubMedGoogle Scholar
  • 68 Olesen C, Steffensen F H, Sorensen H T, Nielsen G L, Olsen J. Pregnancy outcome following prescription for sumatriptan.  Headache. 2000;  40(1) 20-24
    CrossrefPubMedGoogle Scholar
  • 69 Friedman B W, Hochberg M L, Esses D et al.. Recurrence of primary headache disorders after emergency department discharge: frequency and predictors of poor pain and functional outcomes.  Ann Emerg Med. 2008;  52(6) 696-704
    CrossrefPubMedGoogle Scholar
  • 70 Gupta M X, Silberstein S D, Young W B, Hopkins M, Lopez B L, Samsa G P. Less is not more: underutilization of headache medications in a university hospital emergency department.  Headache. 2007;  47(8) 1125-1133
    CrossrefPubMedGoogle Scholar
  • 71 Peterlin B L, Rapoport A M. Clinical pharmacology of the serotonin receptor agonist, zolmitriptan.  Expert Opin Drug Metab Toxicol. 2007;  3(6) 899-911
    CrossrefPubMedGoogle Scholar

Jerry W SwansonM.D. F.A.C.P. 

Professor of Neurology, Department of Neurology

Mayo Clinic, 200 First Street SW, Rochester, MN 55905

eMail: jwswanson@mayo.edu

      >